A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Phase 2
252
about 2.2 years
18–70
36 sites in AL, AZ, CA +16
About this study
Researchers are testing a treatment called PF-07275315 for people with moderate-to-severe asthma. The trial is seeking participants who are 18 to 70 years old and have had moderate-to-severe asthma for at least 12 months that is not well controlled. Participants will receive PF-07275315 or a placebo, which is an inactive substance that looks like the medicine being studied. The treatment will be given as multiple shots in the clinic over the course of 12 weeks. It will last about 9.5 months and involve 10 visits to the clinic.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take PF-07275315
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12, Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), and AEs/SAEs leading to treatment discontinuation
Secondary: Change from baseline in Asthma Control Questionnaire-5 (ACQ-5) total score at Week 12, Change from baseline in Asthma Quality of Life Questionnaire (AQLQ) global score at Week 12, Change from baseline in post-bronchodilator % Predicted FEV1 at all time points, Change from baseline in post-bronchodilator % Predicted FVC at all time points, Change from baseline in post-bronchodilator FEV1 at all time points, Change from baseline in post-bronchodilator FEV1/FVC Ratio at all time points, Change from baseline in post-bronchodilator FVC at all time points, Change from baseline in pre-bronchodilator % Predicted FEV1 at all time points
Respiratory